🇺🇸 FDA
Pipeline program

IO-202

IO-202-CL-001

Phase 1 mab completed

Quick answer

IO-202 for AML With Monocytic Differentiation is a Phase 1 program (mab) at BeOne Medicines with 1 ClinicalTrials.gov record(s).

Program details

Company
BeOne Medicines
Indication
AML With Monocytic Differentiation
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials